| abstract |
The invention relates to an application of a gene marker in the prediction of the prognosis effect of non-small cell lung cancer, a prediction device and a computer-readable medium, and belongs to the technical field of medical molecular biology. Through NGS detection and benefit time follow-up analysis of patients treated with afatinib, a molecular marker that can be used to predict the efficacy of afatinib treatment in patients with EGFR -positive non-small cell lung cancer was found: Mutation signature APOBEC, which can effectively differentiate If the patients with primary resistance to afatinib are identified, the clinical program should be adjusted in time, so that the patients can benefit better. |